

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

Christoph Renner,¹ Pier Luigi Zinzani,² Rémy Gressin,³ Dirk Klingbiel,⁴ Pierre-Yves Dietrich,⁵ Felicitas Hitz,⁶ Mario Bargetzi,⁷ Walter Mingrone,⁸ Giovanni Martinelli,⁹ Andreas Trojan,¹⁰ Krimo Bouabdallah,¹¹ Andreas Lohri,¹² Emmanuel Gyan,¹³ Christine Biaggi,⁴ Sergio Cogliatti,⁶ Francesco Bertoni,¹⁴ Michele Ghielmini,¹⁴ Peter Brauchli,⁴ and Nicolas Ketterer¹⁵ on behalf of the Swiss SAKK and the French GOELAMS group from the European Mantle Cell Lymphoma Network

¹University Hospital Zurich, Zurich, Switzerland; ²Institute of Hematology, University of Bologna, Bologna, Italy; ³Service d'Hématologie, University Hospital, and INSERM-Unit 823, Joseph Fourier University, Albert Bonniot Research Centre Institute, Grenoble, France and the GOELAMS group; ⁴SAKK Coordinating Center, Bern, Switzerland; ⁵University Hospital HUG, Geneva, Switzerland; ⁶Kantonsspital St. Gallen, St. Gallen, Switzerland; ⁷Kantonsspital Aarau, Aargau, Switzerland; ⁸Kantonsspital Olten, Olten, Switzerland; ⁹IEO Onco-hematology Department, Milano, Italy; ¹⁰OnkoZentrum Zürich, Zürich, Switzerland; ¹¹University Hospital, Bordeaux, France and the GOELAMS group; ¹²Medical University Clinic, Oncology, Kantonsspital Liestal, Switzerland; ¹³University Hospital, Tours, France and the GOELAMS group; ¹⁴Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland, and ¹⁵University Hospital CHUV, Lausanne, Switzerland

Citation: Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich P-Y, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, and Ketterer N on behalf of the Swiss SAKK and the French GOELAMS group from the European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. *Haematologica* 2012;97(7):1085-1091. doi:10.3324/haematol.2011.053173

Online Supplementary Table S1. Prior treatment regimens.

UPN	Treatment Regimen 1	Treatment Regimen 2	Treatment Regimen 3
1	R-CHOP		
2	CHOP followed by BEAM + ASCT	Rituximab monotherapy	Experimental vaccine
3	R-Gemcitabine	R-ACOD	
4	Rituximab monotherapy	CHOP	R-EPOCH
5	R-CHOP	R-Chlorambucil	
6	R-CHOP	R-EPOCH	
7	ARA-C monotherapy	R-Gemcitabine	
8	R-CHOP	Chlorambucil	R-Chlorambucil
9	Hyper-CVAD		
10	R-CHOP	R-ICE	
11	R-CHOP	R-CHOP	Velcade monotherapy
12	R-CHOP	ICE	
13	Rituximab monotherapy	CHOP	
14	Gemcitabine monotherapy	R-Chlorambucil	
15	R- Hyper-CVAD		
16	R-CHOP/R-DHAP	Rituximab induction followed by maintenance	
17	Chlorambucil	Rituximab monotherapy	R-CVP
18	R-CHOP		
19	Rituximab monotherapy	Rituximab monotherapy	
20	R-Hyper-CVAD	Endoxan 3g/m ² followed by BEAM + ASCT	Rituximab monotherapy
21	Chlorambucil		
22	R-CHOP		
23	Chloraminophene		
24	R-CHOP/R-DHAP followed by BEAM + ASCT	R-VPM + ARA-C	
25	R-CHOP		
26	R-CHOP/R-DHAP	R-CHOP	
27	6x R-CHOP		
28	CHOP	Velcade	
29	R-CHOP	GA101 (Roche) Trial BO20999	
30	R-Chlorambucil	R-VAD-Chloraminophene	R-CHOP
31	R-DHAP	R-CHOP	
32	R-Chlorambucil		
33	R-CHOP		
35	R-ACOD	BEAM + ASCT	
36	Chlorambucil	RIT with 177 Lu/anti-CD20 antibody (trial)	Chlorambucil

ACOD: adriamycin, cyclophosphamide, oncovin, prednisone; ARA-C: cytarabine; BEAM: BCNU, etoposide, ARA-C, melphalan; CHOP: cyclophosphamide, hydroxydaunorubicin, prednisone; CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone; DHAP: dexamethasone, cytarabine, cisplatin; EPOCH: etoposide, prednisone, oncovin, cyclophosphamide, hydroxydaunorubicin; hyper-CVAD: CVAD + HD-MTX, ARA-C; ICE: ifosfamide, carboplatin, etoposide; ASCT: autologous stem cell transplantation; R: combination with rituximab; R-CVP: prednisone, oncovin, cyclophosphamide. RIT: radioimmunotherapy; VAD: vincristine, doxorubicin, dexamethasone; VPM: verapamil.